Imaging solution developer Imagin Medical said yesterday it recruited the initial subjects in a first-in-human study of its i/Blue Imaging System.
The company is developing the ultrasensitive i/Blue Imaging System which it hopes will “establish a new standard of care” for detecting certain cancers and visualizing the surgical field during minimally invasive surgery, with an initial focus on bladder cancer.
Initial procedures are currently being coordinated with the lead investigator, the Vancouver, Canada-based company said.
“We are excited to see the study underway and are fortunate to be working with the University of Rochester, one of the nation’s leading academic medical centers, on this important step forward for Imagin,” prez & CE Jim Hutchens said in a press release.
The study, which was launched early last month, aims to explore the minimal dwell time needed for the detection of cancerous cells using protoporphyrin IX near infrared fluorescence, Imagin Medical said.